Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy

NCT06660355 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Chronic Graft-versus-host Disease (cGVHD)

Interventions

DRUG: Ruxolitinib
DRUG: Prednisone

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]